Archive: Company News
Company News: #investEU – Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform
– European Investment Bank (EIB) provides EUR 10 million immediately, with a further EUR 15 million available upon meeting certain milestones
– Transaction is guaranteed by the European Fund for Strategic Investments (EFSI), the heart of the Investment Plan for Europe
– Financing allows strategic expansion and further development of Unyvero Platform
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, and the European Investment Bank (EIB) today announced that the EIB granted Curetis a EUR 25 million senior, unsecured loan. The financing is the first growth capital loan under the European Growth Finance Facility (EGFF), launched in November 2016.
Company News: ISA Pharmaceuticals Advances Personalized Cancer Treatment
– Next-generation immunotherapy called MyISA® for individual cancer patients
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the recently established Tumor neoantigEn SeLection Alliance (TESLA), a global cancer neoantigen alliance forged by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute, which was announced on December 1st, 2016.
Company News: Curetis Publishes Business and Financial Update for the First Nine Months 2016
– U.S. FDA trial completed with excellent top-line data
– Leading position in genetic antimicrobial resistance biomarker testing strengthened by GEAR acquisition
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2016 and provided an outlook to coming months.
Company News: World Antibiotics Day: Reduction of infection risk in femoral head fractures by 66% with antibiotic-loaded bone cement from Heraeus
– New study from Great Britain verifies the advantages of antibiotic-loaded bone cement from Heraeus with femoral head fractures
– Older patients with concomitant diseases profit from locally applied antibiotics
Good news for World Antibiotics Day on November 18th. As local substances carriers, antibiotic-loaded bone cements from Heraeus help in the battle against implant-associated infections in orthopaedics and trauma surgery to prevent infection. This is demonstrated by a new randomised study* from Great Britain in which the use of double-loaded antibiotic bone cement following femoral head fracture led to a significant 66% reduction in infection risk with primary hip arthroplasties, as compared with bone cement with only one antibiotic.